<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11681425</article-id><article-id pub-id-type="doi">10.3389/fonc.2024.1477166</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oncology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Predicting distant metastasis of bladder cancer using multiple machine learning models: a study based on the SEER database with external validation</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zou</surname><given-names>Xin Chang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2789006"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Rao</surname><given-names>Xue Peng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Jian Biao</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Jie</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Chao</surname><given-names>Hai Chao</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/960695"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zeng</surname><given-names>Tao</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1927793"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University</institution>, <addr-line>Nanchang</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Department of Urology, Second Affiliated Hospital of Nanchang University</institution>, <addr-line>Nanchang</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Jacopo Troisi, University of Salerno, Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Bernhard Ralla, Charit&#x000e9; University Medicine Berlin, Germany</p><p>Yanyang Jin, First Affiliated Hospital of Jinzhou Medical University, China</p></fn><corresp id="fn001">*Correspondence: Tao Zeng, <email xlink:href="mailto:taozeng40709@sina.com">taozeng40709@sina.com</email>
</corresp><fn fn-type="equal" id="fn003"><p>&#x02020;These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>13</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>14</volume><elocation-id>1477166</elocation-id><history><date date-type="received"><day>07</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2024 Zou, Rao, Huang, Zhou, Chao and Zeng</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Zou, Rao, Huang, Zhou, Chao and Zeng</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Background and purpose</title><p>Distant metastasis in bladder cancer is linked to poor prognosis and significant mortality. Machine learning (ML), a key area of artificial intelligence, has shown promise in the diagnosis, staging, and treatment of bladder cancer. This study aimed to employ various ML techniques to predict distant metastasis in patients with bladder cancer.</p></sec><sec><title>Patients and methods</title><p>Patients diagnosed with bladder cancer in the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2021 were included in this study. After a rigorous screening process, a total of 4,108 patients were selected for further analysis, divided in a 7:3 ratio into a training cohort and an internal validation cohort. In addition, 118 patients treated at the Second Affiliated Hospital of Nanchang University were included as an external validation cohort. Features were filtered using the least absolute shrinkage and selection operator (LASSO) regression algorithm. Based on the significant features identified, three ML algorithms were utilized to develop prediction models: logistic regression, support vector machine (SVM), and linear discriminant analysis (LDA). The predictive performance of the three models was evaluated by obtaining the area under the receiver operating characteristic (ROC) curve (AUC), the precision, the accuracy, and the F1 score.</p></sec><sec><title>Results</title><p>According to the statistical results, the final probability of distant metastasis in the population was 12.0% (<italic>n</italic> = 495). LASSO regression analysis revealed that age, chemotherapy, tumor size, the examination of non-regional lymph nodes, and regional lymph node evaluation were significantly associated with distant metastasis of bladder cancer. In the internal validation cohort, the prediction accuracy rates for logistic regression, SVM, and LDA were 0.874, 0.877, and 0.845, respectively. The precision rates were 0.805, 0.769, and 0.827, respectively, and the F1 scores were 0.821, 0.819, and 0.835, respectively. The ROC curve demonstrated that the AUC for all models was greater than 0.7. In the external validation cohort, the prediction accuracy rates for logistic regression, SVM, and LDA were 0.856, 0.848, and 0.797, respectively, with the ROC curve indicating that the AUC also exceeded 0.7. The precision rates were 0.877, 0.718, and 0.736, respectively, and the F1 scores were 0.797, 0.778, and 0.762, respectively. Among the algorithms used, logistic regression demonstrated better predictive efficiency than the other two methods. The top three variables with the highest importance scores in the logistic regression were non-regional lymph nodes, age, and chemotherapy.</p></sec><sec><title>Conclusion</title><p>The prediction model developed using three ML algorithms demonstrated strong accuracy and discriminative capability in predicting distant metastasis in patients with bladder cancer. This might help clinicians in understanding patient prognosis and in formulating personalized treatment strategies, ultimately improving the overall prognosis of patients with bladder cancer.</p></sec></abstract><kwd-group><kwd>machine learning</kwd><kwd>bladder cancer</kwd><kwd>SEER database</kwd><kwd>distant metastasis</kwd><kwd>predictive value</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Innovative Research Group Project of the National Natural Science Foundation of China
</institution><institution-id institution-id-type="doi">10.13039/100014718</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn001">82260598</award-id></award-group><award-group><funding-source id="cn002"><institution-wrap><institution>Jiangxi Provincial Department of Science and Technology
</institution><institution-id institution-id-type="doi">10.13039/501100010857</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn002">20225BCJ22009</award-id></award-group></funding-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by the National Natural Science Foundation of China (no. 82260598) and the Jiangxi Provincial Academic and Technical Leader Training Program in Major Disciplines (no. 20225BCJ22009).</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="1"/><equation-count count="0"/><ref-count count="29"/><page-count count="13"/><word-count count="2877"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Genitourinary Oncology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Bladder cancer (Bca) is one of the most common malignant tumors of the urinary tract. As the ninth most prevalent malignant tumor globally, its incidence and prevalence are increasing year by year. Approximately 550,000 patients are newly diagnosed with Bca each year (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Men tend to have a higher incidence, and smoking is believed to be a contributing factor (<xref rid="B3" ref-type="bibr">3</xref>). Based on the ability of the tumor to invade, Bca can be classified into non-muscle-invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC), and metastatic forms of the disease (<xref rid="B4" ref-type="bibr">4</xref>). Approximately 70% of newly diagnosed cases are NMIBC, while approximately 30% are diagnosed as MIBC, frequently with metastatic characteristics. Half of the patients with muscle-invasive disease will die from metastases within 2 years. Compared with the 5-year survival rate of 77% for all stages of Bca, the 5-year survival rate for metastatic Bca is only 5% (<xref rid="B5" ref-type="bibr">5</xref>&#x02013;<xref rid="B7" ref-type="bibr">7</xref>). Therefore, it is critical to develop models for the prediction of distant metastasis of Bca.</p><p>As an essential branch of artificial intelligence (AI), machine learning (ML) develops predictive models by automatically learning from large datasets to improve prediction algorithms. This advancement assists clinicians in identifying high-risk patients and in evaluating the prognosis of various diseases (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). Diagnostic and prognostic models built using ML algorithms based on pathomic data have demonstrated remarkable efficiency in distinguishing patients with Bca from those with glandular cystitis, as well as in predicting the survival outcomes of BCa (<xref rid="B10" ref-type="bibr">10</xref>). Network analysis methods rooted in ML frameworks can effectively identify biomarkers linked to immunotherapy responses, resulting in robust predictions for precision oncology (<xref rid="B11" ref-type="bibr">11</xref>). Furthermore, a ML model utilizing full-sequence MRI can accurately forecast the depth of invasion of Bca prior to surgery, helping clinicians in recognizing pathological features associated with tumor invasion ahead of invasive procedures (<xref rid="B12" ref-type="bibr">12</xref>). In addition, ML has been widely applied in prostate cancer and kidney cancer research, and it also holds significant potential in various benign conditions, such as urinary tract stones (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>).</p><p>In this study, data on patients with Bca and their clinical and pathological characteristics were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2021. Our aim was to utilize ML algorithms to develop a reliable model for the prediction of distant metastasis of Bca, thereby providing clinical support for treatment decisions and individualized prognosis assessment.</p></sec><sec id="s2"><title>Patients and methods</title><sec id="s2_1"><title>Patients</title><p>Detailed data of patients with Bca from 17 registration centers between 2000 and 2021 were collected from SEER*Stat (version 8.4.3), including the demographic, clinical, and pathological characteristics. The inclusion criterion comprised patients diagnosed with Bca during this time frame. The exclusion criteria were cases with unknown race, unknown pathological grade, unknown radiotherapy status, unknown tumor size or blank records, unknown non-regional lymph nodes, and unknown T, N, or M stage, as well as unknown regional lymph node examination results. <xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref> illustrates the complete screening process. As SEER is a public database and all records are de-identified, no additional ethical approval was required.</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Surveillance, Epidemiology, and End Results (SEER) database screening and research flowchart.</p></caption><graphic xlink:href="fonc-14-1477166-g001" position="float"/></fig><p>The external validation cohort comprised 118 eligible patients diagnosed with Bca between 2016 and 2020. Upon review and analysis, a total of 18 patients were found to have ultimately developed distant metastasis. The final follow-up was scheduled for December 2023. This study was approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University, with a waiver of informed consent.</p></sec><sec id="s2_2"><title>Screening for clinical and pathological features</title><p>The variables selected included demographic characteristics (i.e., age, sex, and race), tumor characteristics (i.e., tumor size, grade, histology, T stage, and N stage), treatment information (e.g., chemotherapy and radiation therapy), and other variables (e.g., regional lymph nodes examined and non-regional lymph nodes). The primary endpoint of this study was the development of distant metastases in Bca. For better analysis, some of the variables were processed in the SEER database. A number of continuous variables, i.e., age, tumor size, regional lymph nodes examined, and non-regional lymph nodes, were transformed into categorical variables. All clinical and pathological features were used in the training set to screen the features most related to the distant metastasis of Bca using least absolute shrinkage and selection operator (LASSO) regression.</p><p>Variables were selected not only for their individual significance but also for their potential interactions and contributions to the overall predictive model. The LASSO regression technique applies a penalty proportional to the absolute value of the coefficient sizes, effectively shrinking some coefficients to zero. This process facilitates variable selection while preventing overfitting, which is particularly important when dealing with high-dimensional datasets. The tuning parameter (<italic>&#x003bb;</italic>) regulates the strength of the penalty: a larger <italic>&#x003bb;</italic> leads to more coefficients being set to zero, thereby highlighting the most important predictors.</p><p>The clinical rationale for selecting these variables is grounded in their established correlations with outcomes in previous studies and clinical guidelines. For instance, age and gender have been shown to significantly influence the prognosis of cancer and the response to treatment. Tumor characteristics such as size, grade, and stage (T and N) are critical in the assessment of the aggressiveness of a cancer and the likelihood of metastasis. In addition, treatment variables, particularly the effects of chemotherapy and radiation therapy on cancer progression, have been well documented and are essential for our analysis. Lastly, examination of regional and non-regional lymph nodes is crucial for the assessment of the metastatic spread, thus helping in the development of predictive models for distant metastasis.</p></sec><sec id="s2_3"><title>Construction of the machine learning model</title><p>As a common linear classifier, logistic regression establishes a regression formula for the classification boundary based on existing data, enabling the accurate identification of binary classification problems. It primarily implements the algorithm through the logistic function, specifically the sigmoid function. Support vector machine (SVM), as a binary classification model, is fundamentally defined as a linear classifier that maximizes the margin in the feature space. By maximizing this margin, SVM can ultimately be transformed into a solution for a convex quadratic programming problem. Linear discriminant analysis (LDA), a classic method in statistics and ML, aims to maximize the separation between samples of different categories while minimizing the scatter within the same category through a projection method, thus achieving linear classification of data.</p><p>The clinical and pathological characteristics identified above were utilized in constructing the ML models. Three types of ML algorithms were trained using a binary classification approach. The training set (70%) was used to train the model, while the validation set (30%) was employed to assess the predictive performance of the model, followed by external validation. A weighted average of the precision, accuracy, and F1 score was employed to minimize the impact of sample imbalance on the evaluation results. The predictive values of logistic regression, SVM, and LDA were compared by calculating the prediction accuracy, precision, F1 score, and the area under the receiver operating characteristic (ROC) curve (AUC).</p></sec><sec id="s2_4"><title>Statistical analysis</title><p>Data analysis was conducted using SPSS 27.0, R language software (version 4.3.1; <ext-link xlink:href="http://www.r-project.org/" ext-link-type="uri">http://www.r-project.org/</ext-link>), and Python language software (<ext-link xlink:href="https://www.python.org/downloads/release/python-380/" ext-link-type="uri">https://www.python.org/downloads/release/python-380/</ext-link>). For the analysis and processing, all categorical variables were expressed as numbers with percentages, and LASSO regression was employed to identify key predictors. LASSO regression was carried out using the glmnet package in R or the scikit-learn package in Python, and the ROC curve was plotted using the matplotlib package in Python.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3_1"><title>Patient characteristics and metastasis</title><p>The characteristics of the training cohort, the internal validation cohort, and the external validation cohort of patients are presented in <xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>. The probabilities of distant metastasis for Bca in the three cohorts were 11.9% (<italic>n</italic> = 343), 12.3% (<italic>n</italic> = 152), and 19.4% (<italic>n</italic> = 14), respectively.</p><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Clinical and pathological characteristics of the patients across the three cohorts.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Variables</th><th valign="middle" align="center" rowspan="1" colspan="1">Training <break/>(<italic>n</italic> = 2,876)</th><th valign="middle" align="center" rowspan="1" colspan="1">Internal validation<break/>(<italic>n</italic> = 1,232)</th><th valign="middle" align="center" rowspan="1" colspan="1">External validation <break/>(n = 118)</th></tr></thead><tbody><tr><th valign="middle" colspan="4" align="left" rowspan="1">Distant metastasis, <italic>n</italic> (%)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="middle" align="center" rowspan="1" colspan="1">2,533 (88.07)</td><td valign="middle" align="center" rowspan="1" colspan="1">1,080 (87.66)</td><td valign="middle" align="center" rowspan="1" colspan="1">100 (84.75)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">343 (11.93)</td><td valign="middle" align="center" rowspan="1" colspan="1">152 (12.34)</td><td valign="middle" align="center" rowspan="1" colspan="1">18 (15.25)</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">Age, <italic>n</italic> (%)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;60 years</td><td valign="middle" align="center" rowspan="1" colspan="1">298 (10.36)</td><td valign="middle" align="center" rowspan="1" colspan="1">139 (11.28)</td><td valign="middle" align="center" rowspan="1" colspan="1">16 (13.56)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;60&#x02013;80 years</td><td valign="middle" align="center" rowspan="1" colspan="1">1,352 (47.01)</td><td valign="middle" align="center" rowspan="1" colspan="1">611 (49.59)</td><td valign="middle" align="center" rowspan="1" colspan="1">55 (46.61)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;80 years</td><td valign="middle" align="center" rowspan="1" colspan="1">1,226 (42.63)</td><td valign="middle" align="center" rowspan="1" colspan="1">482 (39.12)</td><td valign="middle" align="center" rowspan="1" colspan="1">47 (39.83)</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">Gender, <italic>n</italic> (%)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Men</td><td valign="middle" align="center" rowspan="1" colspan="1">2,050 (71.28)</td><td valign="middle" align="center" rowspan="1" colspan="1">832 (67.53)</td><td valign="middle" align="center" rowspan="1" colspan="1">81 (68.64)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Women</td><td valign="middle" align="center" rowspan="1" colspan="1">826 (28.72)</td><td valign="middle" align="center" rowspan="1" colspan="1">400 (32.47)</td><td valign="middle" align="center" rowspan="1" colspan="1">37 (31.36)</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">Race, <italic>n</italic> (%)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;White</td><td valign="middle" align="center" rowspan="1" colspan="1">2,512 (87.34)</td><td valign="middle" align="center" rowspan="1" colspan="1">1,061 (86.12)</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Black</td><td valign="middle" align="center" rowspan="1" colspan="1">158 (5.49)</td><td valign="middle" align="center" rowspan="1" colspan="1">162 (13.15)</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Other</td><td valign="middle" align="center" rowspan="1" colspan="1">206 (7.16)</td><td valign="middle" align="center" rowspan="1" colspan="1">9 (0.73)</td><td valign="middle" align="center" rowspan="1" colspan="1">118 (100)</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">Histology, <italic>n</italic> (%)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;TCC</td><td valign="middle" align="center" rowspan="1" colspan="1">2,483 (86.34)</td><td valign="middle" align="center" rowspan="1" colspan="1">1,049 (85.15)</td><td valign="middle" align="center" rowspan="1" colspan="1">98 (83.05)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;NTCC</td><td valign="middle" align="center" rowspan="1" colspan="1">393 (13.66)</td><td valign="middle" align="center" rowspan="1" colspan="1">183 (14.85)</td><td valign="middle" align="center" rowspan="1" colspan="1">20 (16.95)</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">Grade, <italic>n</italic> (%)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Grade I</td><td valign="middle" align="center" rowspan="1" colspan="1">34 (1.18)</td><td valign="middle" align="center" rowspan="1" colspan="1">17 (1.38)</td><td valign="middle" align="center" rowspan="1" colspan="1">18 (15.25)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Grade II</td><td valign="middle" align="center" rowspan="1" colspan="1">150 (5.22)</td><td valign="middle" align="center" rowspan="1" colspan="1">73 (5.93)</td><td valign="middle" align="center" rowspan="1" colspan="1">6 (5.09)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Grade III</td><td valign="middle" align="center" rowspan="1" colspan="1">833 (28.96)</td><td valign="middle" align="center" rowspan="1" colspan="1">464 (37.66)</td><td valign="middle" align="center" rowspan="1" colspan="1">36 (30.51)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Grade IV</td><td valign="middle" align="center" rowspan="1" colspan="1">1,859 (64.64)</td><td valign="middle" align="center" rowspan="1" colspan="1">678 (55.03)</td><td valign="middle" align="center" rowspan="1" colspan="1">58 (49.15)</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">Radiotherapy, <italic>n</italic> (%)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="middle" align="center" rowspan="1" colspan="1">160 (5.56)</td><td valign="middle" align="center" rowspan="1" colspan="1">53 (4.30)</td><td valign="middle" align="center" rowspan="1" colspan="1">79 (66.95)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">2,716 (94.44)</td><td valign="middle" align="center" rowspan="1" colspan="1">1,179 (95.70)</td><td valign="middle" align="center" rowspan="1" colspan="1">39 (33.05)</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">Chemotherapy, <italic>n</italic> (%)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="middle" align="center" rowspan="1" colspan="1">1,074 (37.34)</td><td valign="middle" align="center" rowspan="1" colspan="1">495 (40.18)</td><td valign="middle" align="center" rowspan="1" colspan="1">47 (39.83)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">1,802 (62.66)</td><td valign="middle" align="center" rowspan="1" colspan="1">737 (59.82)</td><td valign="middle" align="center" rowspan="1" colspan="1">71 (60.17)</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">Tumor size, <italic>n</italic> (%)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x02265;3 cm</td><td valign="middle" align="center" rowspan="1" colspan="1">2,304 (80.11)</td><td valign="middle" align="center" rowspan="1" colspan="1">998 (81.01)</td><td valign="middle" align="center" rowspan="1" colspan="1">95 (80.51)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;3 cm</td><td valign="middle" align="center" rowspan="1" colspan="1">572 (19.89)</td><td valign="middle" align="center" rowspan="1" colspan="1">234 (18.99)</td><td valign="middle" align="center" rowspan="1" colspan="1">23 (19.49)</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">Non-regional lymph nodes, <italic>n</italic> (%)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="middle" align="center" rowspan="1" colspan="1">2,502 (87.00)</td><td valign="middle" align="center" rowspan="1" colspan="1">1,047 (84.98)</td><td valign="middle" align="center" rowspan="1" colspan="1">102 (86.44)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">374 (13.00)</td><td valign="middle" align="center" rowspan="1" colspan="1">185 (15.02)</td><td valign="middle" align="center" rowspan="1" colspan="1">16 (13.56)</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">T stage, <italic>n</italic> (%)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;T1</td><td valign="middle" align="center" rowspan="1" colspan="1">314 (10.92)</td><td valign="middle" align="center" rowspan="1" colspan="1">150 (12.18)</td><td valign="middle" align="center" rowspan="1" colspan="1">12 (10.17)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;T2</td><td valign="middle" align="center" rowspan="1" colspan="1">1,801 (62.62)</td><td valign="middle" align="center" rowspan="1" colspan="1">751 (60.96)</td><td valign="middle" align="center" rowspan="1" colspan="1">84 (71.19)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;T3</td><td valign="middle" align="center" rowspan="1" colspan="1">406 (14.12)</td><td valign="middle" align="center" rowspan="1" colspan="1">146 (11.85)</td><td valign="middle" align="center" rowspan="1" colspan="1">12 (10.17)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;T4</td><td valign="middle" align="center" rowspan="1" colspan="1">355 (12.34)</td><td valign="middle" align="center" rowspan="1" colspan="1">185 (15.02)</td><td valign="middle" align="center" rowspan="1" colspan="1">10 (8.47)</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">N stage, <italic>n</italic> (%)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;N0</td><td valign="middle" align="center" rowspan="1" colspan="1">2,522 (87.69)</td><td valign="middle" align="center" rowspan="1" colspan="1">1,053 (85.47)</td><td valign="middle" align="center" rowspan="1" colspan="1">61 (51.69)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;N1</td><td valign="middle" align="center" rowspan="1" colspan="1">189 (6.57)</td><td valign="middle" align="center" rowspan="1" colspan="1">73 (5.93)</td><td valign="middle" align="center" rowspan="1" colspan="1">20 (16.95)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;N2</td><td valign="middle" align="center" rowspan="1" colspan="1">157 (5.46)</td><td valign="middle" align="center" rowspan="1" colspan="1">103 (8.36)</td><td valign="middle" align="center" rowspan="1" colspan="1">19 (16.10)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;N3</td><td valign="middle" align="center" rowspan="1" colspan="1">8 (0.28)</td><td valign="middle" align="center" rowspan="1" colspan="1">3 (0.24)</td><td valign="middle" align="center" rowspan="1" colspan="1">18 (15.26)</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">Regional nodes examined, <italic>n</italic> (%)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;10</td><td valign="middle" align="center" rowspan="1" colspan="1">2,663 (92.60)</td><td valign="middle" align="center" rowspan="1" colspan="1">1,168 (94.81)</td><td valign="middle" align="center" rowspan="1" colspan="1">111 (94.07)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;10&#x02013;20</td><td valign="middle" align="center" rowspan="1" colspan="1">137 (4.76)</td><td valign="middle" align="center" rowspan="1" colspan="1">37 (3.00)</td><td valign="middle" align="center" rowspan="1" colspan="1">3 (2.54)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;20</td><td valign="middle" align="center" rowspan="1" colspan="1">76 (2.64)</td><td valign="middle" align="center" rowspan="1" colspan="1">27 (2.19)</td><td valign="middle" align="center" rowspan="1" colspan="1">4 (3.39)</td></tr></tbody></table><table-wrap-foot><fn><p>&#x0201c;Other&#x0201d; included American Indian/Alaska Native/Asian/Pacific Islander.</p></fn><fn><p>
<italic>TCC</italic>, transitional cell carcinoma; <italic>NTCC</italic>, non-transitional cell carcinoma</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3_2"><title>Identification of significant features</title><p>All clinical and pathological characteristics were analyzed using LASSO regression. The results indicated that age, chemotherapy, tumor size, non-regional lymph nodes, and regional lymph node examination were the significant variables associated with the distant metastasis of Bca, as detailed in <xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>.</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>
<bold>(A)</bold> Least absolute shrinkage and selection operator (LASSO) coefficient distribution of the clinical and pathological characteristics. <bold>(B)</bold> LASSO regression analysis was performed using the minimum criterion and a 10-fold cross-validation method. By introducing a penalty adjustment parameter (<italic>&#x003bb;</italic>), the coefficients of the features are compressed towards zero, enabling automatic feature selection.</p></caption><graphic xlink:href="fonc-14-1477166-g002" position="float"/></fig></sec><sec id="s3_3"><title>Construction and evaluation of machine models</title><p>Three ML models were developed using the significant variables identified earlier. A weighted average of the precision, accuracy, and the F1 score was utilized to minimize the effects of sample imbalance on the evaluation results. In the internal validation cohort, the prediction accuracy rates for logistic regression, SVM, and LDA were 0.874, 0.877, and 0.845, respectively. The accuracy rates were 0.805, 0.769, and 0.827, respectively, and the F1 scores were 0.821, 0.819, and 0.835, respectively. The AUC (95% CI) values were 0.701 (0.634&#x02013;0.767), 0.701 (0.641&#x02013;0.766), and 0.701 (0.635&#x02013;0.780), respectively. In the external validation cohort, the prediction accuracy rates for logistic regression, SVM, and LDA were 0.856, 0.848, and 0.797, respectively. The precision rates were 0.877, 0.718, and 0.736, respectively, and the F1 scores were 0.797, 0.778, and 0.762, respectively. The AUC (95% CI) values were 0.740 (0.682&#x02013;0.795), 0.740 (0.674&#x02013;0.792), and 0.740 (0.685&#x02013;0.796), respectively. Details can be found in <xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3</bold>
</xref>. These results indicate that all three models can effectively predict distant metastasis in Bca. However, after comprehensive comparison, logistic regression was found to have the best predictive value and identification ability. The top three variables with logistic regression importance scores were non-regional lymph nodes, age, and chemotherapy (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4</bold>
</xref>).</p><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>Receiver operating characteristic (ROC) curves of the internal validation cohort <bold>(A)</bold> and the external validation cohort <bold>(B)</bold>.</p></caption><graphic xlink:href="fonc-14-1477166-g003" position="float"/></fig><fig position="float" id="f4"><label>Figure&#x000a0;4</label><caption><p>Logistic regression importance scores.</p></caption><graphic xlink:href="fonc-14-1477166-g004" position="float"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Distant metastasis of Bca significantly impacts the survival rates and treatment prospects of patients. The common sites of metastasis include the liver, kidneys, and bones. Patients with Bca face an increased risk of death due to distant metastasis (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). Those with localized Bca often experience an excellent quality of life and progression-free survival with aggressive treatment. Despite advancements in various targeted therapies and immunotherapies, distant metastasis remains highly lethal when it occurs (<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>). The metastatic spread in patients with Bca is believed to be random and unpredictable. Although early systemic treatment for Bca has made progress and is somewhat effective in preventing tumor progression, some individuals still inevitably develop recurrent or metastatic disease (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). Therefore, it is crucial to develop new models for predicting the metastasis of Bca.</p><p>ML, a subfield of AI, emerged from the intersection of statistics and computer science. Among the algorithms that demonstrate superior performance, LDA and SVM are the most commonly recognized (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). The continuous advancement of computing systems and recognition software has contributed to the popularity of ML-based systems. These systems are capable of performing complex tasks in bioinformatics and medical imaging, assisting healthcare professionals in improving the diagnostic accuracy, predicting disease progression, and even exploring new therapeutic avenues (<xref rid="B23" ref-type="bibr">23</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>).&#x000a0;A retrospective study by Denget al. showed that a ML model combining radiomic features and clinical variables could accurately predict the pathological grade of Bca (<xref rid="B26" ref-type="bibr">26</xref>). In addition, the quantitative assessment of tumor-infiltrating lymphocytes using ML mitigates the inter- and intra-observer variability, effectively predicting survival in MIBC and identifying patients who may benefit from immunotherapy or treatment adjustments (<xref rid="B27" ref-type="bibr">27</xref>). Liu et&#x000a0;al. predicted lung metastasis in Bca by developing a nomogram model; however, this model did not include all distant metastases and highlighted the need for improved algorithmic approaches (<xref rid="B28" ref-type="bibr">28</xref>). In the study by Chen et&#x000a0;al., multiple clinical variables were utilized to develop a nomogram for predicting distant metastasis in patients with urothelial Bca (<xref rid="B29" ref-type="bibr">29</xref>). In this research, a more advanced ML algorithm was employed, incorporating AI methods to successfully predict distant metastasis in Bca. ML utilizes advanced algorithms to analyze various clinical variables and integrate multiple data sources, resulting in a more comprehensive assessment of the condition of a patient. This approach improves the diagnostic accuracy and reduces the likelihood of misdiagnosis (<xref rid="B9" ref-type="bibr">9</xref>).</p><p>Our research utilized three ML models: logistic regression, SVM, and LDA. After screening the clinical variables and pathological characteristics using LASSO regression, we incorporated the identified significant variables and features into the construction of our ML models. In the internal validation cohort, we evaluated the predictive capability of the three models by calculating the prediction accuracy, precision, F1 score, and the AUC. The results indicated that all three models effectively predicted distant metastasis in Bca. This was further confirmed with the external validation cohort. By utilizing the model described above, the stage and the pathological type of patients with Bca can be predicted in real time, allowing for targeted treatment and follow-up for those at high risk of distant metastasis. However, this study has several limitations. Firstly, as a retrospective analysis based on the SEER database, it may have lacked certain potentially important factors, such as vascular invasion and preoperative laboratory results. In addition, patients with unknown variable information were excluded, which means that the results were inevitably impacted by selection bias. Secondly, variations in the sequencing of radiotherapy and chemotherapy, the types of radiation used, and the chemotherapy agents administered may have affected the likelihood of Bca metastasizing to distant sites. Finally, while we have validated our model using an external cohort, it is essential to include additional clinical and molecular biological features in the future to enhance its predictive power in complex clinical settings. Furthermore, multicenter prospective studies are essential for the development of more robust algorithms, such as deep learning and ensemble models. These studies should also focus on comparing model performance across different groups (such as gender and age) in multicenter external validations to further verify our findings.</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusion</title><p>In summary, we successfully developed and validated three ML models for the prediction of distant metastasis in Bca. In particular, the logistic regression algorithm achieved better prediction results. The application of these models can assist clinicians in making more accurate treatment decisions and in providing personalized follow-up management, ultimately improving patient prognosis.</p></sec></body><back><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The studies involving humans were approved by Biomedical Research Ethics Committee of the Second Affiliated Hospital of Nanchang University. The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants&#x02019; legal guardians/next of kin because it&#x02019;s a retrospective study, and is difficult to obtain informed consent, and no loss to the patient.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>XZ: Data curation, Formal Analysis, Investigation, Methodology, Software, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. XR: Supervision, Writing &#x02013; review &#x00026; editing. JH: Writing &#x02013; review &#x00026; editing. JZ: Supervision, Validation, Writing &#x02013; review &#x00026; editing. TZ: Funding acquisition, Supervision, Writing &#x02013; review &#x00026; editing. HC: Methodology, Supervision, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source>. (<year>2021</year>) <volume>71</volume>(<issue>3</issue>):<page-range>209&#x02013;49</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Richters</surname><given-names>A</given-names></name><name><surname>Aben</surname><given-names>KKH</given-names></name><name><surname>Kiemeney</surname><given-names>LALM</given-names></name></person-group>. <article-title>The global burden of urinary bladder cancer: an update</article-title>. <source>World J Urol</source>. (<year>2020</year>) <volume>38</volume>(<issue>8</issue>):<page-range>1895&#x02013;904</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00345-019-02984-4</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lobo</surname><given-names>N</given-names></name><name><surname>Afferi</surname><given-names>L</given-names></name><name><surname>Moschini</surname><given-names>M</given-names></name><name><surname>Mostafid</surname><given-names>H</given-names></name><name><surname>Porten</surname><given-names>S</given-names></name><name><surname>Psutka</surname><given-names>SP</given-names></name><etal/></person-group>. <article-title>Epidemiology, screening, and prevention of bladder cancer</article-title>. <source>Eur Urol Oncol</source>. (<year>2022</year>) <volume>5</volume>(<issue>6</issue>):<page-range>628&#x02013;39</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.euo.2022.10.003</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Comp&#x000e9;rat</surname><given-names>E</given-names></name><name><surname>Amin</surname><given-names>MB</given-names></name><name><surname>Cathomas</surname><given-names>R</given-names></name><name><surname>Choudhury</surname><given-names>A</given-names></name><name><surname>De Santis</surname><given-names>M</given-names></name><name><surname>Kamat</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Current best practice for bladder cancer:a narrative review of diagnostics and treatments</article-title>. <source>Lancet</source>. (<year>2022</year>) <volume>400</volume>(<issue>10364</issue>):<page-range>1712&#x02013;21</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0140-6736(22)01188-6</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patel</surname><given-names>VG</given-names></name><name><surname>Oh</surname><given-names>WK</given-names></name><name><surname>Galsky</surname><given-names>MD</given-names></name></person-group>. <article-title>Treatment of muscle-invasive and advanced bladder cancer in 2020</article-title>. <source>CA Cancer J Clin</source>. (<year>2020</year>) <volume>70</volume>(<issue>5</issue>):<page-range>404&#x02013;23</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3322/caac.21631</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ghatalia</surname><given-names>P</given-names></name><name><surname>Kaur</surname><given-names>J</given-names></name><name><surname>Sonpavde</surname><given-names>G</given-names></name></person-group>. <article-title>Muscle invasive bladder cancer: where is the field headed</article-title>? <source>Expert Opin Biol Ther</source>. (<year>2023</year>) <volume>23</volume>(<issue>9</issue>):<page-range>913&#x02013;27</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/14712598.2023.2238607</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dobruch</surname><given-names>J</given-names></name><name><surname>Oszczud&#x00142;owski</surname><given-names>M</given-names></name></person-group>. <article-title>Bladder cancer : current challenges and future directions</article-title>. <source>Medicina(Kaunas)</source>. (<year>2021</year>) <volume>57</volume>(<issue>8</issue>):<elocation-id>749</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/medicina57080749</pub-id>
<pub-id pub-id-type="pmid">34440955</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moore</surname><given-names>NS</given-names></name><name><surname>McWilliam</surname><given-names>A</given-names></name><name><surname>Aneja</surname><given-names>S</given-names></name></person-group>. <article-title>Bladder cancer radiation oncology of the future : prognostic modelling, radiomics, and treatment planning with artificial intelligence</article-title>. <source>Semin Radiat Oncol</source>. (<year>2023</year>) <volume>33</volume>(<issue>1</issue>):<page-range>70&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.semradonc.2022.10.009</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borhani</surname><given-names>S</given-names></name><name><surname>Borhani</surname><given-names>R</given-names></name><name><surname>Kajdacsy-Balla</surname><given-names>A</given-names></name></person-group>. <article-title>Artificial intelligence: A promising frontier in bladder cancer diagnosis and outcome prediction</article-title>. <source>Crit Rev Oncol Hematol</source>. (<year>2022</year>) <volume>171</volume>:<elocation-id>103601</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.critrevonc.2022.103601</pub-id>
<pub-id pub-id-type="pmid">35065220</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Clinical use of machine learning-based pathomics signature for diagnosis and survival prediction of bladder cancer</article-title>. <source>Cancer Sci</source>. (<year>2021</year>) <volume>112</volume>(<issue>7</issue>):<page-range>2905&#x02013;14</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/cas.14927</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Ha</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>I</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Im</surname><given-names>SH</given-names></name><etal/></person-group>. <article-title>Network-based machine learning approach to predict immunotherapy response in cancer patients</article-title>. <source>Nat Commun</source>. (<year>2022</year>) <volume>13</volume>(<issue>1</issue>):<fpage>3703</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-022-31535-6</pub-id>
<pub-id pub-id-type="pmid">35764641</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamad</surname><given-names>J</given-names></name><name><surname>McCloskey</surname><given-names>H</given-names></name><name><surname>Milowsky</surname><given-names>MI</given-names></name><name><surname>Royce</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name></person-group>. <article-title>Bladder preservation in muscle-invasive bladder cancer: a comprehensive review</article-title>. <source>Int Braz J Urol</source>. (<year>2020</year>) <volume>46</volume>(<issue>2</issue>):<page-range>169&#x02013;84</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1590/S1677-5538.IBJU.2020.99.01</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Ji</surname><given-names>Z</given-names></name></person-group>. <article-title>Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>14</volume>:<elocation-id>1171420</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2023.1171420</pub-id>
<pub-id pub-id-type="pmid">37063886</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alfred Witjes</surname><given-names>J</given-names></name><name><surname>Max Bruins</surname><given-names>H</given-names></name><name><surname>Carri&#x000f3;n</surname><given-names>A</given-names></name><name><surname>Cathomas</surname><given-names>R</given-names></name><name><surname>Comp&#x000e9;rat</surname><given-names>E</given-names></name><name><surname>Efstathiou</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>European association of urology guidelines on muscle-invasive and metastatic bladder cancer : summary of the 2023 guidelines</article-title>. <source>Eur Urol</source>. (<year>2024</year>) <volume>85</volume>(<issue>1</issue>):<fpage>17</fpage>&#x02013;<lpage>31</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.eururo.2023.08.016</pub-id>
<pub-id pub-id-type="pmid">37858453</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Safiri</surname><given-names>S</given-names></name><name><surname>Kolahi</surname><given-names>AA</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Meraz-Munoz</surname><given-names>A</given-names></name><name><surname>North</surname><given-names>SA</given-names></name><name><surname>Alimohamed</surname><given-names>NS</given-names></name><etal/></person-group>. <article-title>Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories,1990-2019:a systematic analysis for the Global Burden of Disease study 2019</article-title>. <source>BMJ Glob Health</source>. (<year>2021</year>) <volume>6</volume>(<issue>11</issue>):<elocation-id>e004128</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/bmjgh-2020-004128</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lopez-Beltran</surname><given-names>A</given-names></name><name><surname>Cookson</surname><given-names>MS</given-names></name><name><surname>Guercio</surname><given-names>BJ</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name></person-group>. <article-title>Advances in diagnosis and treatment of bladder cancer</article-title>. <source>BMJ</source>. (<year>2024</year>) <volume>384</volume>:<elocation-id>e076743</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/bmj-2023-076743</pub-id>
<pub-id pub-id-type="pmid">38346808</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>DM</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Kitchlu</surname><given-names>A</given-names></name><name><surname>Meraz-Munoz</surname><given-names>A</given-names></name><name><surname>North</surname><given-names>SA</given-names></name><name><surname>Alimohamed</surname><given-names>NS</given-names></name><etal/></person-group>. <article-title>Defining cisplatin eligibility in patients with muscle-invasive bladder cancer</article-title>. <source>Nat Rev Urol</source>. (<year>2021</year>) <volume>18</volume>(<issue>2</issue>):<page-range>104&#x02013;14</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41585-020-00404-6</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kwon</surname><given-names>WA</given-names></name><name><surname>Seo</surname><given-names>HK</given-names></name></person-group>. <article-title>Emerging agents for the treatment of metastatic urothelial cancer</article-title>. <source>Investig Clin Urol</source>. (<year>2021</year>) <volume>62</volume>(<issue>3</issue>):<page-range>243&#x02013;55</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4111/icu.20200597</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Charpentier</surname><given-names>M</given-names></name><name><surname>Gutierrez</surname><given-names>C</given-names></name><name><surname>Guillaudeux</surname><given-names>T</given-names></name><name><surname>Verhoest</surname><given-names>G</given-names></name><name><surname>Pedeux</surname><given-names>&#x000a0;</given-names></name></person-group>. <article-title>Noninvasive urine-based tests to diagnose or detect recurrence of bladder cancer</article-title>. <source>Cancers (Basel)</source>. (<year>2021</year>) <volume>13</volume>(<issue>7</issue>):<elocation-id>1650</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/cancers13071650</pub-id>
<pub-id pub-id-type="pmid">33916038</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ruan</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer</article-title>. <source>Clin Epigenet</source>. (<year>2021</year>) <volume>13</volume>(<issue>1</issue>):<fpage>91</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13148-021-01073-x</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferro</surname><given-names>M</given-names></name><name><surname>Falagario</surname><given-names>UG</given-names></name><name><surname>Barone</surname><given-names>B</given-names></name><name><surname>Maggi</surname><given-names>M</given-names></name><name><surname>Crocetto</surname><given-names>F</given-names></name><name><surname>Busetto</surname><given-names>GM</given-names></name><etal/></person-group>. <article-title>Artificial intelligence in the advanced diagnosis of bladder cancer-comprehensive literature review and future advancement</article-title>. <source>Diagnostics (Basel)</source>. (<year>2023</year>) <volume>13</volume>(<issue>13</issue>):<elocation-id>2308</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/diagnostics13132308</pub-id>
<pub-id pub-id-type="pmid">37443700</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barberis</surname><given-names>E</given-names></name><name><surname>Khoso</surname><given-names>S</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Falasca</surname><given-names>M</given-names></name><name><surname>Gennari</surname><given-names>A</given-names></name><name><surname>Dondero</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Precision medicine approaches with metabolomics and artificial intelligence</article-title>. <source>Int J Mol Sci</source>. (<year>2022</year>) <volume>23</volume>(<issue>19</issue>):<elocation-id>11269</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms231911269</pub-id>
<pub-id pub-id-type="pmid">36232571</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benning</surname><given-names>L</given-names></name><name><surname>Peintner</surname><given-names>A</given-names></name><name><surname>Peintner</surname><given-names>L</given-names></name></person-group>. <article-title>Advances in and the applicability of machine learning-based screening and early detection approaches for cancer: A primer</article-title>. <source>Cancers (Basel)</source>. (<year>2022</year>) <volume>14</volume>(<issue>3</issue>):<elocation-id>623</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/cancers14030623</pub-id>
<pub-id pub-id-type="pmid">35158890</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi</surname><given-names>RY</given-names></name><name><surname>Coyner</surname><given-names>AS</given-names></name><name><surname>Kalpathy-Cramer</surname><given-names>J</given-names></name><name><surname>Chiang</surname><given-names>MF</given-names></name><name><surname>Campbell</surname><given-names>JP</given-names></name></person-group>. <article-title>Introduction to machine learning, neural networks, and deep learning</article-title>. <source>Transl Vis Sci Technol</source>. (<year>2020</year>) <volume>9</volume>(<issue>2</issue>):<elocation-id>14</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1167/tvst.9.2.14</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Castiglioni</surname><given-names>I</given-names></name><name><surname>Rundo</surname><given-names>L</given-names></name><name><surname>Codari</surname><given-names>M</given-names></name><name><surname>Di Leo</surname><given-names>G</given-names></name><name><surname>Salvatore</surname><given-names>C</given-names></name><name><surname>Interlenghi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>AI applications to medical images: From machine learning to deep learning</article-title>. <source>Phys Med</source>. (<year>2021</year>) <volume>83</volume>:<fpage>9</fpage>&#x02013;<lpage>24</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ejmp.2021.02.006</pub-id>
<pub-id pub-id-type="pmid">33662856</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>Xiong</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Machine learning models combining computed tomography semantic features and selected clinical variables for accurate prediction of the pathological grade of bladder cancer</article-title>. <source>Front Oncol</source>. (<year>2023</year>) <volume>13</volume>:<elocation-id>1166245</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fonc.2023.1166245</pub-id>
<pub-id pub-id-type="pmid">37223680</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Ni</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Jiao</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Quantitative assessment of tumor-infiltrating lymphocytes using machine learning predicts survival in muscle-invasive bladder cancer</article-title>. <source>J Clin Med</source>. (<year>2022</year>) <volume>11</volume>(<issue>23</issue>):<elocation-id>7081</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/jcm11237081</pub-id>
<pub-id pub-id-type="pmid">36498655</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>FZ</given-names></name><name><surname>Zhang</surname><given-names>PY</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>HX</given-names></name></person-group>. <article-title>Development and validation a model for predicting overall survival of bladder cancer with lung metastasis: a population-based study</article-title>. <source>Eur J Med Res</source>. (<year>2023</year>) <volume>28</volume>(<issue>1</issue>):<fpage>279</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s40001-023-01261-w</pub-id>
<pub-id pub-id-type="pmid">37559152</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Ye</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Fan</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Constructing and validating nomograms to predict risk and prognostic factors of distant metastasis in urothelial bladder cancer patients: a population-based retrospective study</article-title>. <source>BMC Urol</source>. (<year>2022</year>) <volume>22</volume>(<issue>1</issue>):<fpage>212</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12894-022-01166-6</pub-id>
<pub-id pub-id-type="pmid">36575440</pub-id>
</mixed-citation></ref></ref-list></back></article>